Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Fletcher

Showing results (191-200 of 326) with videos related to

Pageof 33
Sort By:
Clinical Pharmacology and Therapeutics|June 29, 2007
The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patientsJ J Kiser, M L Carten, C L Aquilante, et al.
The Journal of Antimicrobial Chemotherapy|July 24, 2019
Assessing the lymphoid tissue bioavailability of antiretrovirals in human primary lymphoid endothelial cells and in miceShetty Ravi Dyavar, Nagsen Gautam, Anthony T Podany, et al.
Clinical Pharmacology and Therapeutics|October 3, 1998
Concentration-controlled zidovudine therapyC V Fletcher, E P Acosta, K Henry, et al.
Plos One|January 17, 2023
A hyperinflammation clinical risk tool, HI5-NEWS2, stratifies hospitalised COVID-19 patients to associate risk of death and effect of early dexamethasone in an observational cohortMichael R Ardern-Jones, Hang T T Phan, Florina Borca, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|June 21, 2021
Role of toll-like receptor 7/8 pathways in regulation of interferon response and inflammatory mediators during SARS-CoV2 infection and potential therapeutic optionsShetty Ravi Dyavar, Rahul Singh, Rohini Emani, et al.
Antiviral Therapy|May 28, 2005
Current status and future prospects of therapeutic drug monitoring and applied clinical pharmacology in antiretroviral therapyMarta Boffito, Edward Acosta, David Burger, et al.
The Lancet. Microbe|April 9, 2021
Assessing whether isoniazid is essential during the first 14 days of tuberculosis therapy: a phase 2a, open-label, randomised controlled trialAndreas Diacon, Sachiko Miyahara, Rodney Dawson, et al.
The Journal of Pediatrics|April 17, 1998
A pilot study of combination therapy with indinavir, stavudine (d4T), and didanosine (ddI) in children infected with the human immunodeficiency virusM W Kline, C V Fletcher, A T Harris, et al.
The Journal of Antimicrobial Chemotherapy|July 27, 2021
Intramuscular and subcutaneous administration of antiretroviral drugs, compared with oral, enhances delivery to lymphoid tissues in BALB/c miceShetty Ravi Dyavar, Sushil Kumar, Nagsen Gautam, et al.
Antimicrobial Agents and Chemotherapy|December 20, 2000
Pharmacological basis for concentration-controlled therapy with zidovudine, lamivudine, and indinavirT N Kakuda, L M Page, P L Anderson, et al.
Pageof 33

Showing results (191-200 of 326) with videos related to

Sort By:
Pageof 33
Clinical Pharmacology and Therapeutics|June 29, 2007
The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patientsJ J Kiser, M L Carten, C L Aquilante, et al.
The Journal of Antimicrobial Chemotherapy|July 24, 2019
Assessing the lymphoid tissue bioavailability of antiretrovirals in human primary lymphoid endothelial cells and in miceShetty Ravi Dyavar, Nagsen Gautam, Anthony T Podany, et al.
Clinical Pharmacology and Therapeutics|October 3, 1998
Concentration-controlled zidovudine therapyC V Fletcher, E P Acosta, K Henry, et al.
Plos One|January 17, 2023
A hyperinflammation clinical risk tool, HI5-NEWS2, stratifies hospitalised COVID-19 patients to associate risk of death and effect of early dexamethasone in an observational cohortMichael R Ardern-Jones, Hang T T Phan, Florina Borca, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|June 21, 2021
Role of toll-like receptor 7/8 pathways in regulation of interferon response and inflammatory mediators during SARS-CoV2 infection and potential therapeutic optionsShetty Ravi Dyavar, Rahul Singh, Rohini Emani, et al.
Antiviral Therapy|May 28, 2005
Current status and future prospects of therapeutic drug monitoring and applied clinical pharmacology in antiretroviral therapyMarta Boffito, Edward Acosta, David Burger, et al.
The Lancet. Microbe|April 9, 2021
Assessing whether isoniazid is essential during the first 14 days of tuberculosis therapy: a phase 2a, open-label, randomised controlled trialAndreas Diacon, Sachiko Miyahara, Rodney Dawson, et al.
The Journal of Pediatrics|April 17, 1998
A pilot study of combination therapy with indinavir, stavudine (d4T), and didanosine (ddI) in children infected with the human immunodeficiency virusM W Kline, C V Fletcher, A T Harris, et al.
The Journal of Antimicrobial Chemotherapy|July 27, 2021
Intramuscular and subcutaneous administration of antiretroviral drugs, compared with oral, enhances delivery to lymphoid tissues in BALB/c miceShetty Ravi Dyavar, Sushil Kumar, Nagsen Gautam, et al.
Antimicrobial Agents and Chemotherapy|December 20, 2000
Pharmacological basis for concentration-controlled therapy with zidovudine, lamivudine, and indinavirT N Kakuda, L M Page, P L Anderson, et al.
Pageof 33